nelfinavir Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
HIV protease inhibitors 1893 159989-64-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nelfinavir
  • viracept
  • nelfinavir mesylate
  • nelfinavir mesilate
A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.
  • Molecular weight: 567.79
  • Formula: C32H45N3O4S
  • CLOGP: 5.84
  • LIPINSKI: 2
  • HAC: 7
  • HDO: 4
  • TPSA: 101.90
  • ALOGS: -5.47
  • ROTB: 10

Drug dosage:

DoseUnitRoute
2.25 g O

Approvals:

DateAgencyCompanyOrphan
March 14, 1997 FDA AGOURON

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Exposure during pregnancy 1339.69 71.10 314 1311 32657 4604710
Foetal exposure during pregnancy 682.97 71.10 172 1453 22997 4614370
Lipodystrophy acquired 515.27 71.10 79 1546 721 4636646
Drug resistance 461.38 71.10 103 1522 8033 4629334
Premature baby 366.62 71.10 89 1536 9962 4627405
Mitochondrial toxicity 347.82 71.10 50 1575 275 4637092
Pregnancy 300.31 71.10 74 1551 8770 4628597
Progressive external ophthalmoplegia 297.50 71.10 36 1589 27 4637340
Viral mutation identified 284.29 71.10 50 1575 1109 4636258
Eyelid ptosis 281.38 71.10 54 1571 1963 4635404
Hypertriglyceridaemia 273.08 71.10 54 1571 2299 4635068
Virologic failure 263.78 71.10 52 1573 2177 4635190
Maternal drugs affecting foetus 261.72 71.10 57 1568 3908 4633459
Caesarean section 252.82 71.10 58 1567 5040 4632327
Congenital anomaly 204.22 71.10 42 1583 2174 4635193
Blood lactic acid increased 203.76 71.10 41 1584 1901 4635466
Atrial septal defect 174.44 71.10 40 1585 3449 4633918
Stillbirth 172.88 71.10 36 1589 1978 4635389
Cryptorchism 155.34 71.10 26 1599 422 4636945
Diplopia 154.78 71.10 41 1584 6410 4630957
Treatment failure 147.39 71.10 47 1578 14100 4623267
Abortion spontaneous 147.24 71.10 47 1578 14145 4623222
Cardiac murmur 147.20 71.10 34 1591 3021 4634346
Immune reconstitution inflammatory syndrome 141.89 71.10 33 1592 3021 4634346
Osteonecrosis 123.99 71.10 40 1585 12424 4624943
Hypospadias 119.60 71.10 23 1602 837 4636530
Pathogen resistance 118.04 71.10 28 1597 2788 4634579
Polydactyly 117.39 71.10 21 1604 510 4636857
Hyperlipidaemia 110.59 71.10 30 1595 5115 4632252
Neonatal disorder 109.22 71.10 21 1604 763 4636604
Portal hypertension 109.10 71.10 23 1602 1336 4636031
Maternal exposure during pregnancy 104.10 71.10 38 1587 17055 4620312
Anaemia 103.11 71.10 58 1567 71502 4565865
HIV infection 101.86 71.10 19 1606 585 4636782
Lactic acidosis 101.29 71.10 34 1591 11922 4625445
Foetal death 94.68 71.10 23 1602 2529 4634838
Abdominal hernia 91.41 71.10 19 1606 1029 4636338
Optic nerve neoplasm 90.96 71.10 11 1614 8 4637359
Hyperlactacidaemia 88.43 71.10 18 1607 878 4636489
Patent ductus arteriosus 87.92 71.10 20 1605 1654 4635713
Aspartate aminotransferase increased 86.83 71.10 37 1588 24901 4612466
Blood lactate dehydrogenase increased 86.28 71.10 27 1598 7576 4629791
Lipoatrophy 85.82 71.10 15 1610 317 4637050
Anaemia neonatal 84.75 71.10 14 1611 208 4637159
Trisomy 21 84.36 71.10 16 1609 539 4636828
Abdominal distension 84.18 71.10 33 1592 17956 4619411
Neutropenia neonatal 81.75 71.10 12 1613 77 4637290
Gynaecomastia 81.13 71.10 20 1605 2335 4635032
Ventricular septal defect 75.94 71.10 19 1606 2356 4635011
Cachexia 74.23 71.10 18 1607 1961 4635406
Nodular regenerative hyperplasia 73.40 71.10 13 1612 297 4637070
Alanine aminotransferase increased 72.79 71.10 34 1591 28339 4609028

Pharmacologic Action:

SourceCodeDescription
ATC J05AE04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Protease inhibitors
MeSH PA D019380 Anti-HIV Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D044966 Anti-Retroviral Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D017320 HIV Protease Inhibitors
MeSH PA D011480 Protease Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agent
FDA EPC N0000175889 Protease Inhibitor
FDA MoA N0000190114 Cytochrome P450 3A Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Human immunodeficiency virus infection indication 86406008 DOID:526
Depressive disorder contraindication 35489007
Diarrhea contraindication 62315008
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Hemophilia contraindication 90935002
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Breastfeeding (mother) contraindication 413712001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.66 acidic
pKa2 11.97 acidic
pKa3 6.63 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Mu-type opioid receptor GPCR Ki 5.23 DRUG MATRIX
D(1A) dopamine receptor GPCR Ki 5.19 DRUG MATRIX
Cytochrome P450 3A4 Enzyme IC50 5.70 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.06 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 4.21 DRUG MATRIX
Beta-3 adrenergic receptor GPCR Ki 4.59 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 4.91 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 5.08 DRUG MATRIX
Kappa-type opioid receptor GPCR Ki 4.84 DRUG MATRIX
Delta-type opioid receptor GPCR Ki 4.63 DRUG MATRIX
Epidermal growth factor receptor Kinase IC50 4.25 DRUG MATRIX
Tyrosine-protein kinase Lck Kinase IC50 4.10 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 5.10 DRUG MATRIX
Thromboxane-A synthase Enzyme IC50 4.68 DRUG MATRIX
Mitogen-activated protein kinase 3 Kinase IC50 4.65 DRUG MATRIX
Mitogen-activated protein kinase 14 Kinase IC50 4.74 DRUG MATRIX
Substance-K receptor GPCR Ki 5.01 DRUG MATRIX
Multidrug resistance protein 1 Transporter IC50 4.70 CHEMBL
Pol polyprotein Enzyme INHIBITOR Ki 11 CHEMBL CHEMBL
Gag-Pol polyprotein Polyprotein WOMBAT-PK
Androgen receptor Transcription factor Ki 4.62 DRUG MATRIX
Arachidonate 15-lipoxygenase Enzyme IC50 4.86 DRUG MATRIX
Progesterone receptor Transcription factor Ki 5.24 DRUG MATRIX
SARS-CoV-2 Virus INHIBITOR EC50 5.53 SCIENTIFIC LITERATURE
Protease Enzyme Ki 10.15 CHEMBL

External reference:

IDSource
4024050 VUID
N0000022055 NUI
C0525005 UMLSCUI
D00899 KEGG_DRUG
108706004 SNOMEDCT_US
4024050 VANDF
006408 NDDF
134527 RXNORM
373445001 SNOMEDCT_US
5162 MMSL
d04118 MMSL
98D603VP8V UNII
159989-65-8 SECONDARY_CAS_RN
CHEMBL584 ChEMBL_ID
CHEMBL1205 ChEMBL_ID
DB00220 DRUGBANK_ID
7494 INN_ID
CHEBI:7496 CHEBI
D019888 MESH_DESCRIPTOR_UI
64143 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
VIRACEPT HUMAN PRESCRIPTION DRUG LABEL 1 52959-289 TABLET, FILM COATED 250 mg ORAL NDA 14 sections
Viracept HUMAN PRESCRIPTION DRUG LABEL 1 53808-0809 TABLET, FILM COATED 625 mg ORAL NDA 14 sections
VIRACEPT HUMAN PRESCRIPTION DRUG LABEL 1 63010-010 TABLET, FILM COATED 250 mg ORAL NDA 19 sections
VIRACEPT HUMAN PRESCRIPTION DRUG LABEL 1 63010-027 TABLET, FILM COATED 625 mg ORAL NDA 19 sections